Literature DB >> 17124514

Progress and obstacles in the development of an AIDS vaccine.

Norman L Letvin1.   

Abstract

Recent experimental observations suggest approaches to immunization that might finally result in at least a partially effective vaccine against infection with HIV-1. In particular, advances in our understanding of the contribution of vaccine-elicited cellular immunity to protecting memory CD4(+) T cells from virus-mediated destruction provide rational strategies for the development of this vaccine. This is therefore an ideal time to review our current understanding of HIV-1 and its control by the immune system, as well as the remaining problems that must be solved to facilitate the development of an effective vaccine against AIDS.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17124514     DOI: 10.1038/nri1959

Source DB:  PubMed          Journal:  Nat Rev Immunol        ISSN: 1474-1733            Impact factor:   53.106


  66 in total

1.  Very few substitutions in a germ line antibody are required to initiate significant domain exchange.

Authors:  Michael Huber; Khoa M Le; Katie J Doores; Zara Fulton; Robyn L Stanfield; Ian A Wilson; Dennis R Burton
Journal:  J Virol       Date:  2010-08-11       Impact factor: 5.103

2.  Alphavirus replicon particles acting as adjuvants promote CD8+ T cell responses to co-delivered antigen.

Authors:  Joseph M Thompson; Alan C Whitmore; Herman F Staats; Robert E Johnston
Journal:  Vaccine       Date:  2008-06-09       Impact factor: 3.641

3.  Preventive and therapeutic applications of neutralizing antibodies to Human Immunodeficiency Virus Type 1 (HIV-1).

Authors:  Rajesh Ringe; Jayanta Bhattacharya
Journal:  Ther Adv Vaccines       Date:  2013-07

4.  Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial.

Authors:  Cornelia L Trimble; Matthew P Morrow; Kimberly A Kraynyak; Xuefei Shen; Michael Dallas; Jian Yan; Lance Edwards; R Lamar Parker; Lynette Denny; Mary Giffear; Ami Shah Brown; Kathleen Marcozzi-Pierce; Divya Shah; Anna M Slager; Albert J Sylvester; Amir Khan; Kate E Broderick; Robert J Juba; Timothy A Herring; Jean Boyer; Jessica Lee; Niranjan Y Sardesai; David B Weiner; Mark L Bagarazzi
Journal:  Lancet       Date:  2015-09-17       Impact factor: 79.321

5.  Efficient mucosal transmissibility but limited pathogenicity of R5 SHIV SF162P3N in Chinese-origin rhesus macaques.

Authors:  Alexandra Mumbauer; Agegenhu Gettie; James Blanchard; Cecilia Cheng-Mayer
Journal:  J Acquir Immune Defic Syndr       Date:  2013-04-15       Impact factor: 3.731

6.  CD40L expressed from the canarypox vector, ALVAC, can boost immunogenicity of HIV-1 canarypox vaccine in mice and enhance the in vitro expansion of viral specific CD8+ T cell memory responses from HIV-1-infected and HIV-1-uninfected individuals.

Authors:  Jun Liu; Qigui Yu; Geoffrey W Stone; Feng Yun Yue; Nicholas Ngai; R Brad Jones; Richard S Kornbluth; Mario A Ostrowski
Journal:  Vaccine       Date:  2008-06-02       Impact factor: 3.641

Review 7.  Viral sequence diversity: challenges for AIDS vaccine designs.

Authors:  Sean P McBurney; Ted M Ross
Journal:  Expert Rev Vaccines       Date:  2008-11       Impact factor: 5.217

8.  A vaccine encoding conserved promiscuous HIV CD4 epitopes induces broad T cell responses in mice transgenic to multiple common HLA class II molecules.

Authors:  Susan Pereira Ribeiro; Daniela Santoro Rosa; Simone Gonçalves Fonseca; Eliane Conti Mairena; Edilberto Postól; Sergio Costa Oliveira; Luiza Guilherme; Jorge Kalil; Edecio Cunha-Neto
Journal:  PLoS One       Date:  2010-06-11       Impact factor: 3.240

9.  Mosaic vaccines elicit CD8+ T lymphocyte responses that confer enhanced immune coverage of diverse HIV strains in monkeys.

Authors:  Sampa Santra; Hua-Xin Liao; Ruijin Zhang; Mark Muldoon; Sydeaka Watson; Will Fischer; James Theiler; James Szinger; Harikrishnan Balachandran; Adam Buzby; David Quinn; Robert J Parks; Chun-Yen Tsao; Angela Carville; Keith G Mansfield; George N Pavlakis; Barbara K Felber; Barton F Haynes; Bette T Korber; Norman L Letvin
Journal:  Nat Med       Date:  2010-02-21       Impact factor: 53.440

10.  The cat and mouse of HIV-1 antibody escape.

Authors:  John R Mascola
Journal:  PLoS Pathog       Date:  2009-09-18       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.